Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AtezoCab: A Phase II Study of Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Non-Measurable Disease

NCT05168618 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT05168618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05168618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AtezoCab: A Phase II Study of Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Non-Measurable Disease
Lead sponsor
University of Utah
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 29, 2022
Completion date
November 30, 2027
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, metastatic prostate adenocarcinoma, stage iv prostate cancer ajcc v8, stage iva prostate cancer ajcc v8, stage ivb prostate cancer ajcc v8